[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Atalar H, Başarir K, Yildiz Y, Sağlik Y: [Prognostic factors in patients with malignant fibrous histiocytoma of the extremities]. Acta Orthop Traumatol Turc; 2007 Aug-Oct;41(4):271-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors in patients with malignant fibrous histiocytoma of the extremities].
  • [Transliterated title] Ekstremite yerleşimli malign fibröz histiyositomlu hastalarda prognostik faktörler.
  • OBJECTIVES: We evaluated prognostic factors in patients with malignant fibrous histiocytoma of the extremity.
  • METHODS: The study included 26 patients (22 males, 4 females; 15 patients < age 60) with a diagnosis of malignant fibrous histiocytoma of the extremity.
  • Clinical and pathological data were analyzed including age, gender, affected extremity, presentation status (primary or recurrent), localization (proximal or distal), size, depth, and grade of the tumor, resection quality, adjuvant therapy, and the presence of distant metastasis at the time of diagnosis.
  • Adjuvant chemotherapy and radiotherapy were administered to 17 patients and 10 patients, respectively.
  • Two patients had distant metastasis at the time of diagnosis while eight patients developed distant metastasis within a mean of 13 months (range 7 to 20 months) postoperatively.
  • CONCLUSION: Patients with high-grade malignant fibrous histiocytoma have a poorer prognosis.
  • [MeSH-major] Extremities. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Recurrence, Local / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180555.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Fu DL, Yang F, Maskay A, Long J, Jin C, Yu XJ, Xu J, Zhou ZW, Ni QX: Primary intestinal malignant fibrous histiocytoma: two case reports. World J Gastroenterol; 2007 Feb 28;13(8):1299-302
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intestinal malignant fibrous histiocytoma: two case reports.
  • Malignant fibrous histiocytoma (MFH) occurs most commonly in the extremities and trunk, but rarely in the intestine.
  • Here we report two cases of primary intestinal MFH.
  • The first case was a 70-year old man admitted for recurrent right lower quadrant abdominal pain.
  • Though the symptoms were not typical, based on histological and immunohistochemical studies, the patients were diagnosed as MFH of the intestine.
  • They were not treated with chemotherapy or radiotherapy and both died within 3 mo.
  • MFH of the intestine is an extremely rare neoplasm with an aggressive biological behavior.
  • Complete surgical excision is preferred, adjuvant chemotherapy or radiotherapy may be advisable.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Intestinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 May;26(3):305-10 [10741601.001]
  • [Cites] Surg Today. 2005;35(4):323-7 [15815852.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Skeletal Radiol. 2003 Nov;32(11):613-8 [14517697.001]
  • [Cites] Dig Dis Sci. 2004 Aug;49(7-8):1156-60 [15387338.001]
  • [Cites] Burns. 2004 Nov;30(7):742-5 [15475153.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Exp Hematol. 1993 Sep;21(10):1342-52 [7689482.001]
  • [Cites] Gastroenterol Jpn. 1993 Aug;28(4):554-63 [7690726.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):91-6 [8548744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):983-94 [8600111.001]
  • [Cites] Pathol Int. 1997 Oct;47(10):718-24 [9361108.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 15;100(2):134-42 [9428357.001]
  • [Cites] Surg Today. 1999;29(2):160-4 [10030742.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):447-8 [10419723.001]
  • [Cites] APMIS. 1999 Sep;107(9):837-42 [10519319.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Surg Today. 2001;31(3):242-5 [11318129.001]
  • (PMID = 17451221.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147015
  •  go-up   go-down


3. Seper L, Schwab R, Kiattavorncharoen S, Büchter A, Bánkfalvi A, Joos U, Piffkó J, Kruse-Loesler B: Malignant fibrous histiocytoma of the face: report of a case. Head Face Med; 2007;3:36
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the face: report of a case.
  • BACKGROUND: Soft tissue sarcomas in the head and neck region are rare and often present a difficult differential diagnosis.
  • The aim of our presentation is to point out the complexity of the diagnosis, treatment and follow up.
  • Four months beforehand, a benign fibrous histiocytoma (BFH) had been removed from the same location by excision biopsy with wide tumour-free resection margins.
  • Excision biopsy of the recurrent lesion revealed a malignant fibrous histiocytoma (MFH).
  • No adjuvant radio- or chemotherapy was administered.
  • DISCUSSION: Malignant transformation of BFH is extremely rare and if so, extended radical surgery may give a fair chance for a favourable outcome even in patients with advanced age.
  • [MeSH-major] Facial Neoplasms / pathology. Facial Neoplasms / surgery. Histiocytoma, Malignant Fibrous / pathology. Histiocytoma, Malignant Fibrous / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neck Dissection / methods. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):212-7 [10971696.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):239-52 [12778019.001]
  • [Cites] Am J Surg Pathol. 1994 Jul;18(7):668-76 [8017561.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • (PMID = 17945018.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2211745
  •  go-up   go-down


Advertisement
4. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer; 2008 Jul 15;113(2):419-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
  • METHODS: A retrospective case review of 22 patients with recurrent or refractory bone or soft-tissue sarcomas who received gemcitabine (at a dose of 675 mg/m(2) intravenously on Days 1 and 8) and docetaxel (at a dose of 75-100 mg/m(2) intravenously on Day 8) was undertaken.
  • RESULTS: The patients (ages 8-23 years) received a total of 109 courses of chemotherapy (median, 4 courses; range, 1-13 courses).
  • Seventeen patients had osteosarcoma, 2 patients had Ewing sarcoma family of tumors (ESFT), 1 patient had a malignant fibrous histiocytoma (MFH), 1 patient had a chondrosarcoma, and 1 patient had an undifferentiated sarcoma.
  • Of the 14 patients evaluable for response, the patient with an MFH achieved a complete response (CR), 3 patients with osteosarcoma achieved a partial response (PR), and 2 patients (1 with ESFT and 1 with osteosarcoma) had stable disease (SD).
  • CONCLUSIONS: In the current study, gemcitabine in combination with docetaxel was found to be well tolerated and demonstrated antitumor activity in children and adolescents with recurrent or refractory osteosarcoma and MFH.
  • Further evaluation of this drug combination is warranted in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Osteosarcoma / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Dose-Response Relationship, Drug. Female. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18484657.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Bölke E, Ruf L, Budach W, Reinecke P, Röhrborn A, Pape H, Schwarz A, Schmitt G, Aul C: Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma. Wien Klin Wochenschr; 2005 Dec;117(23-24):833-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
  • Malignant fibrous histiocytoma (MFH) is a soft-tissue sarcoma created from fibroblast cells and characterized by a high rate of metastasis or recurrence with poor prognosis.
  • We report a case of initially well differentiated (G1) MFH of the trunk in a 33-year-old woman.
  • Histopathological findings indicated a stromal tumor consisting of spindle cells, and immunohistochemical examination of resected specimens established the definite diagnosis of poorly differentiated MFH (G3).
  • There was a high local recurrence and metastasis rate, and the patient was treated with radiotherapy and conventional chemotherapy followed by tandem high-dose chemotherapy and peripheral blood stem-cell transplantation.
  • We review the clinical picture of the tumor in this patient and discuss its diagnosis, pathogenesis and treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Histiocytoma, Malignant Fibrous / therapy. Radiotherapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Thoracic Surgery. Transplantation, Autologous. Treatment Outcome


6. Tejwani A, Kobayashi W, Chen YL, Rosenberg AE, Yoon S, Raskin KA, Rosenthal DI, Nielsen GP, Hornicek FJ, Delaney TF: Management of acral myxoinflammatory fibroblastic sarcoma. Cancer; 2010 Dec 15;116(24):5733-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of acral myxoinflammatory fibroblastic sarcoma.
  • BACKGROUND: Acral myxoinflammatory fibroblastic sarcoma (AMFS) is a rare, low-grade sarcoma that commonly affects the distal extremities.
  • From the published cases, therapy for AMFS to date has been comprised of excision or amputation, with limited use of radiotherapy (RT) or chemotherapy.
  • METHODS: A retrospective review of all cases of AMFS identified in the Sarcoma Database in the Department of Radiation Oncology at the study institution was conducted.
  • Treatment records and data from follow-up visits of patients were reviewed.
  • The average total dose was 56.4 Gray (Gy).
  • One patient presented with recurrent disease and was treated with resection, and both pre- and postoperative RT.
  • He was free of disease 23 months after his last treatment.
  • CONCLUSIONS: Data were consistent with local control of distal extremity sarcomas with resection and RT, suggesting that limb-sparing surgery with this treatment combination is an appropriate option in the limb-sparing control of patients with AMFS, even those with positive surgical margins.
  • [MeSH-major] Extremities. Histiocytoma, Malignant Fibrous / radiotherapy. Histiocytoma, Malignant Fibrous / surgery. Sarcoma / radiotherapy. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20737559.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Abe T, Yamanaka K, Nakata W, Mori N, Sekii K, Yoshioka T, Itatani H: [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report]. Hinyokika Kiyo; 2007 Apr;53(4):241-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report].
  • Abdominal computed tomography and magnetic resonance imaging revealed a large retroperitoneal tumor adjacent to the aorta and the renal vessels.
  • Histopathological examination showed a malignant fibrous histiocytoma (MFH).
  • Two cycles of systemic chemotherapy with pirarubicin, vincritine and cyclophosphamide were ineffective, then we tried concurrent cisplatin and radiation therapy.
  • Chemoradiation therapy showed a marked decrease in the size of the tumor, and the patient also recovered from right lumbar pain without serious side effects.
  • After chemoradiation therapy, we performed tumorectomy.
  • He suffered from repeated recurrence and metastases of MFH afterwards.
  • We performed repeatedly concurrent cisplatin and radiation therapy for the recurrent and metastatic tumor sites, and chemoradiation therapy led to regression of the tumors every time.
  • Concurrent cisplatin and radiation therapy might be an effective treatment for unresectable MFH.
  • [MeSH-major] Cisplatin / therapeutic use. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515074.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. McTiernan A, Whelan JS: A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma; 2004;8(2-3):71-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.
  • PURPOSE: To determine the response and toxicity of docetaxel in recurrent osteosarcoma and related spindle cell tumours of bone.
  • Diagnosis was: conventional osteosarcoma, 12 patients; periosteal osteosarcoma, one patient; and malignant fibrous histiocytoma of bone, one patient.
  • Initial chemotherapy had been with doxorubicin and cisplatin in 10 patients, and multiagent regimens in four.
  • Nine had been treated with second line chemotherapy before receiving docetaxel.
  • CONCLUSION: Docetaxel at this dose and schedule is well tolerated, but is not associated with significant activity in patients with relapsed osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 [1671606.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] Sarcoma. 2003;7(1):13-7 [18521364.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):733-7 [10213206.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2341-54 [10561296.001]
  • [Cites] Ann Intern Med. 1989 Aug 15;111(4):273-9 [2569287.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):1016-9 [7547214.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1084-93 [7850705.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):132-9 [10776972.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):259-67 [11210963.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):604-10 [11237379.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):190-2 [11783082.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):710-5 [12586810.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(4):488-94 [12751380.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):384-8 [8094466.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):741-4 [8756366.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):750-8 [9053501.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1071-9 [9060547.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] J Chemother. 1998 Feb;10(1):69-76 [9531078.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2452-8 [9667263.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jul;25(7):539-42 [12847320.001]
  • (PMID = 18521398.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395610
  •  go-up   go-down


9. Takeuchi A, Tsuchiya H, Shirai T, Hayashi K, Nishida H, Tomita K: Occlusive dressing for large soft tissue defects following soft tissue tumor excision. J Orthop Sci; 2009 Jul;14(4):385-90
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occlusive dressing for large soft tissue defects following soft tissue tumor excision.
  • BACKGROUND: Reconstructive surgery using pedicles or free muscle-skin flaps and skin grafting reduces wound complications and promotes favorable limb function; however, the sacrifice of normal tissue remains problematic and complicated.
  • However, their effectiveness for treating soft tissue defects following a soft tissue tumor excision has not been fully elucidated.
  • The purpose of this study was to evaluate the effectiveness and safety of an occlusive dressing treatment method for soft tissue defects following soft tissue tumor excisions.
  • METHODS: We retrospectively reviewed eight patients (three men, five women) whose wounds were treated with polyurethane foam occlusive dressings to allow reconstruction of the soft tissue defect following soft tissue tumor excision.
  • The treatment periods, incidence of complications, and ultimate outcomes were evaluated.
  • Mean treatment periods were 21.6 weeks (range 13.5-44.0 weeks).
  • One patient with a recurrent malignant fibrous histiocytoma (MFH) who had a history of radiotherapy required a posterior thigh flap 44 weeks after the surgery.
  • Recurrence due to a positive surgical margin was observed in only one patient with recurrent MFH.
  • CONCLUSIONS: This treatment method is simple, safe, and reliable.
  • We concluded that the highly favorable indications of this treatment are ideal for patients who wish to avoid sacrificing their normal tissue, have no history of radiotherapy before surgery, and do not require chemotherapy or radiotherapy after the operation.
  • [MeSH-major] Occlusive Dressings. Reconstructive Surgical Procedures / methods. Soft Tissue Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Esthetics. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Lower Extremity. Middle Aged. Pain Measurement. Postoperative Care / methods. Probability. Retrospective Studies. Risk Assessment. Sampling Studies. Time Factors. Upper Extremity. Wound Healing / physiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662471.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Akhter SA, McGinty J, Konys JJ, Giesting RM, Merrill WH, Wagoner LE: Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation. J Heart Lung Transplant; 2004 Dec;23(12):1447-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent primary cardiac malignant fibrous histiocytoma following orthotopic heart transplantation.
  • Malignant fibrous histiocytoma (MFH) is an extremely rare primary cardiac tumor.
  • We describe a young patient who underwent orthotopic heart transplantation for an unresectable right ventricular MFH and presented 7 years later with a local recurrence in the native right atrium.
  • This was treated by complete resection of the right atrial tumor and adjuvant chemotherapy.
  • This case represents the only reported long-term survival following cardiac transplantation for MFH and describes our management strategy for local recurrence in this patient.
  • [MeSH-major] Heart Neoplasms / surgery. Heart Transplantation. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607678.001).
  • [ISSN] 1053-2498
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kozuka T, Kiura K, Katayama H, Fujii N, Ishimaru F, Ikeda K, Ueoka H, Hamasaki S, Yoshino T, Kashihara Y, Date H, Tanimoto M, Harada M: Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. Anticancer Res; 2002 Sep-Oct;22(5):2939-44
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.
  • BACKGROUND: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series.
  • The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established.
  • CASE REPORT: We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT).
  • One patient with malignant fibrous histiocytoma recurred with multiple lung metastases.
  • This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin.
  • During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested.
  • Another patient with malignant hemangiopericytoma was treated by tandem high-dose ICE regimen supported by autologous PBSCT after the 3rd removal of abdominal tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Neoplasm Recurrence, Local / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / therapy. Humans. Ifosfamide / administration & dosage. Male. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12530021.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 3
  •  go-up   go-down


12. Milicic D, Juretic A, Bulum J, Saric N, Bisof V, Jelic I, Jelasic D: Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases. J Card Surg; 2007 Nov-Dec;22(6):513-6
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant fibrous histiocytoma of the heart with skeletal muscles metastases.
  • Malignant fibrous histiocytoma is an extremely rare primary malignant tumor of the heart.
  • The prognosis is poor with an average survival time of one year.
  • We report a case of recurrent left atrial malignant fibrous histiocytoma initially misdiagnosed as myxoma.
  • The patient underwent repeated surgical resections followed by chemotherapy.
  • Despite adjuvant chemotherapy, 18 months after initial diagnosis, definitive tumor relapse in left atrium was diagnosed.
  • This is the 48th case of primary cardiac fibrous malignant histiocytoma reported in the literature.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Muscle Neoplasms / diagnosis. Muscle, Skeletal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039217.001).
  • [ISSN] 0886-0440
  • [Journal-full-title] Journal of cardiac surgery
  • [ISO-abbreviation] J Card Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Kitazono I, Saigenji H: [Long-term survival of malignant fibrous histiocytoma of the chest wall by multidisciplinary treatment]. Kyobu Geka; 2007 Mar;60(3):221-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival of malignant fibrous histiocytoma of the chest wall by multidisciplinary treatment].
  • We report a case of malignant fibrous histiocytoma (MFH) of the chest wall.
  • A 70-year-old man admitted for recurrent chest wall tumor diagnosed for MFH histologically and resected 7 months and 13 months before admission.
  • Chest computed tomography (CT) revealed a tumor located at right posterior chest wall.
  • In May 1997, resection of the tumor was done (the 3rd operation), but metastasis to the ribs (the 4th operation), subcutaneous tissue (the 5th operation), and local recurrence (the 6th operation) was found within 4 years postoperatively.
  • Resection was done for each metastasis, and postoperative radiotherapy (66 Gy) and chemotherapy (CYVADIC) were done.
  • Multidisciplinary treatment may provide longer survival for patients with MFH of the chest wall.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Histiocytoma, Malignant Fibrous / therapy. Thoracic Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Radiotherapy Dosage. Surgical Mesh. Survivors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352141.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CYVADIC protocol
  •  go-up   go-down


14. Sugihara T, Fujimura T, Kume H, Homma Y: Successful treatment of metastatic malignant fibrous histiocytoma of the kidney. Urol Int; 2010;85(1):118-20
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic malignant fibrous histiocytoma of the kidney.
  • Malignant fibrous histiocytoma (MFH) of the kidney is a rare sarcoma that often undergoes local recurrence and/or distant metastasis.
  • We present the case of a 46-year-old male suffering from renal MFH with pulmonary metastasis, who has undergone complete response for 3 years after surgical resection and MAID chemotherapy.
  • He is now well, and without any evidence of recurrent disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Histiocytoma, Malignant Fibrous / therapy. Kidney Neoplasms / therapy. Lung Neoplasms / therapy. Nephrectomy. Thoracoscopy
  • [MeSH-minor] Biopsy. Chemotherapy, Adjuvant. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Mesna / administration & dosage. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20516674.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


15. Jin GP, Zhao M, Qi JX, Jiang HG, Yu SG: [Malignant fibrous histiocytoma of head and neck: clinical analysis of 21 cases]. Ai Zheng; 2003 May;22(5):523-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrous histiocytoma of head and neck: clinical analysis of 21 cases].
  • BACKGROUND & OBJECTIVE: Malignant fibrous histiocytoma (MFH) is a type of pleomorphic neoplastic diseases with complex pathological structure.
  • This study was designed to investigate the clinical and pathological features and improve the diagnosis and treatment.
  • METHODS: To summarize and analyze the clinical experiences of 21 cases of MFH at head and neck proved histologically from June 1984 to June 1999 treated in Department of Head and Neck Surgery, Henan Tumor Hospital.
  • CONCLUSION: MFH at head and neck region is a kind of malignant disease with high recurrent rate and the cervical lymph node metastasis rate was 57.1%.
  • Amplified radical surgery is the first choice of treatment.
  • The second surgery has special value to the recurrent patients.
  • Radiotherapy alone or chemotherapy alone is not effective to MFH of head and neck region.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12753717.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Shioya T, Yuzuriha R, Maejima K, Mizutani S, Nambu K, Hoshino A, Shibuya T, Tokunaga A, Matsumoto K, Tajiri T: Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy. Clin J Gastroenterol; 2008 Oct;1(3):122-126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four-year survival of a patient with malignant fibrous histiocytoma of the liver treated with surgery and chemotherapy.
  • Malignant fibrous histiocytoma of the liver is an extremely rare tumor.
  • Histopathologically, the tumor was diagnosed as a primary storiform-pleomorphic-type malignant fibrous histiocytoma of the liver.
  • One year after the radical operation, the patient developed recurrences in other organs.
  • She received 17 cycles of chemotherapy with etoposide, ifosfamide, and cisplatin.
  • The recurrent tumors decreased in size, but new recurrences in other organs occurred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1992 Sep;21(3):290-2 [1328016.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):620-3 [17085355.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):386-91 [10390563.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W481-9 [17056878.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Mt Sinai J Med. 2005 Jan;72(1):50-2 [15682264.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1331-9 [15446552.001]
  • (PMID = 26193650.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemotherapy / Liver / Malignant fibrous histiocytoma / Sarcoma / Surgery
  •  go-up   go-down


17. Matsumoto S, Ahmed AR, Kawaguchi N, Manabe J, Matsushita Y: Results of surgery for malignant fibrous histiocytomas of soft tissue. Int J Clin Oncol; 2003 Apr;8(2):104-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgery for malignant fibrous histiocytomas of soft tissue.
  • BACKGROUND: To address the prognosis and the role of surgery in the management of patients with malignant fibrous histiocytoma (MFH), strict definition and accurate evaluation of local recurrence is mandated, together with adequate gross and microscopic evaluation of the achieved surgical margins.
  • METHODS: One hundred and twenty-three patients with MFH were retrospectively analyzed regarding prognostic factors of the disease, which included the following: (1).
  • primary or recurrent, (2).
  • adjuvant chemotherapy, (4). size, (5).
  • RESULTS: Local recurrence after primary surgery done at the authors' institute was the most significant prognostic factor, where 20 of 123 patients developed local recurrence ( P < 0.0001).
  • The local recurrence rate for each surgical procedure was 75% for intralesional, 44.4% for marginal, 30.8% for inadequate wide, 12.3% for adequate wide, and 5% for curative procedures.
  • In patients with a history of recurrent tumor or infiltrative pattern, local recurrence was not observed after a curative procedure, but occurred even after an adequate wide procedure.
  • CONCLUSION: To improve the prognosis of MFH, surgical prevention of local recurrence is essential.
  • An adequate wide procedure for primary tumors and a curative procedure for recurrent tumors and tumors with an infiltrative pattern provide safe surgical margins.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local / pathology. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Reoperation. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12720103.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Pirayesh A, Chee Y, Helliwell TR, Hershman MJ, Leinster SJ, Fordham MV, Poston GJ: The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature. Eur J Surg Oncol; 2001 Aug;27(5):491-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature.
  • AIM: Ten percent of soft tissue sarcomas (STS) arise in the retroperitoneal tissues.
  • The prognosis for patients with retroperitoneal sarcoma is poor with a 5-year survival rate between 12% and 70%.
  • Patient, tumour and treatment variables were analysed including use of adjuvant therapy and survival status.
  • RESULTS: Eighteen patients underwent surgery for primary disease, four patients were treated for recurrent disease or metastases.
  • The tumours were seven liposarcomas, six leiomyosarcomas, three malignant fibrous histiocytomas, two rhabdomyosarcomas, two malignant schwannomas and two undifferentiated sarcomas.
  • Six primary tumours were completely excised, five patients received radiotherapy and five received chemotherapy.
  • Five patients received radiotherapy and five received chemotherapy.
  • Adjuvant therapy was not associated with higher survival rates.
  • Adjuvant radiotherapy and chemotherapy do not appear to be any proven benefit and the single most important prognostic factor is aggressive successful en bloc resection of the primary tumour.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neurilemmoma / surgery. Prognosis. Retrospective Studies. Sarcoma / surgery. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Harcourt Publishers Limited.
  • (PMID = 11504522.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 53
  •  go-up   go-down


19. Nakamura T, Kusuzaki K, Seto M, Matsumine A, Uchida A: Case report: recurrence of soft tissue MFH in bone due to minute intravenous tumor emboli detected by MRI. Oncol Rep; 2003 Nov-Dec;10(6):1957-60
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: recurrence of soft tissue MFH in bone due to minute intravenous tumor emboli detected by MRI.
  • We recently encountered a case with local recurrence of malignant fibrous histiocytoma (MFH) in the bone after wide resection, caused by minute intravenous tumor emboli which were retrospectively detected in MR imaging.
  • The tumor was diagnosed to be MFH, therefore a wide resection was performed; although the tumor was closely attached to the periosteum, it was not difficult to dissect the tumor subperiosteally from the cortex of the femur.
  • The patient received postoperative brachytherapy, but no chemotherapy.
  • Such intravenous tumor emboli have recently been implicated in the development of regional bone metastasis near the site of the primary lesion in cases of malignant soft tissue tumors.
  • It is therefore emphasized that MR images should be carefully reviewed for the presence of such intravenous tumor emboli before surgery in cases of high-grade malignant sarcomas.
  • As at the time of writing, our patient remains alive and disease-free, with no evidence of any local recurrence or distant metastasis after wide tumor resection for the recurrent tumor.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / metabolism. Magnetic Resonance Imaging / methods. Recurrence. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534725.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • [Transliterated title] Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten. Auswertung von 603 Fällen.
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • Liposarcoma and malignant fibrous histiocytoma were the most often diagnosed subgroups at 24% and 22.6%, respectively.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • For optimal treatment of soft tissue sarcomas, we suggest obtaining expert second opinion to ensure adequate surgical therapy and precise indications for radiation and chemotherapy.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prevalence of primary breast sarcoma is low, occurring in fewer than 1% of women with breast malignancies.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Overall median survival of patients with breast sarcoma was 58 months.
  • Patients with angiosarcoma had a poorer outcome than other sarcoma patients.
  • Twelve of 18 patients (67%) died of angiosarcoma, compared with 11 of 32 patients (34%) of all other sarcoma patients combined.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.
  • [MeSH-major] Breast Neoplasms. Sarcoma

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C, Steinau HU: MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients. Langenbecks Arch Surg; 2009 Mar;394(2):313-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.
  • BACKGROUND: Undifferentiated pleomorphic sarcoma/NOS (not otherwise specified; former pleomorphic and storiform MFH) of the extremities is a common malignant soft tissue tumor in adults.
  • The objective of this study is to determine prognostic factors for the outcome after surgical treatment with respect to the recent developments in classification.
  • METHODS: From 1996 to 2004, 140 undifferentiated pleomorphic sarcomas/NOS were identified out of 1,200 soft tissue sarcomas of the extremities that were treated at our institution and recorded in a prospective database.
  • All tumors were retrospectively analyzed regarding prognostic factors of the disease, including patient's background (primary or recurrent), histological grade (G2/G3), adjuvant chemotherapy and radiotherapy, size (T1-2) and depth of the tumor, and surgical margins (R0, R1, R2).
  • There was a significant difference between the group presenting with primary tumors (5-year survival: 84%, p < 0.05) and recurrent tumors (5-year survival: 62%, p < 0.05).
  • CONCLUSIONS: In terms of OS and ILR, primary or recurrence, negative surgical margins, size and grading had a highly significant influence, whereas the site of surgery and adjuvant chemotherapy, adjuvant radiation and tumor depth did not.
  • Prognosis for patients with undifferentiated pleomorphic sarcoma of the extremities depends predominantly on adequate wide resection of the primary tumor.
  • [MeSH-major] Extremities / surgery. Histiocytoma, Malignant Fibrous / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2719-25 [12860950.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):391-405 [8604805.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Chirurg. 1993 Jul;64(7):517-26 [8375201.001]
  • [Cites] Cancer. 1964 Nov;17:1445-55 [14223761.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 2004 Dec;33(12):602-8 [15641745.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):104-9 [12720103.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] J Natl Cancer Inst. 1989 Oct 4;81(19):1496-9 [2778839.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):510-5 [12592363.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] Pathologe. 1996 Mar;17(2):116-21 [8650138.001]
  • [Cites] Am J Clin Pathol. 1998 Nov;110(5):660-70 [9802353.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):390-6 [3052763.001]
  • [Cites] Bull Cancer. 2004 Nov;91(11):853-60 [15582889.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):16-22 [11823689.001]
  • [Cites] Pathol Int. 2002 Sep;52(9):595-606 [12406189.001]
  • [Cites] Plast Reconstr Surg. 2004 Jan;113(1):222-30; discussion 231-2 [14707640.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Cancer. 1978 Jun;41(6):2250-66 [207408.001]
  • [Cites] Chirurg. 1988 Apr;59(4):265-71 [3383685.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1340-5 [15446553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6 [12601173.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):445-53 [9230909.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer. 1977 Apr;39(4):1672-85 [192434.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Praxis (Bern 1994). 1998 Aug 19;87(34):1061-5 [9757789.001]
  • (PMID = 18584203.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


24. Issakov J, Merimsky O, Gutman M, Kollender Y, Lev-Chelouche D, Abu-Abid S, Lifschitz-Mercer B, Inbar M, Klausner JM, Meller I: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations. Ann Surg Oncol; 2000 Mar;7(2):155-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
  • BACKGROUND: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery.
  • METHODS: Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan.
  • The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels.
  • Some nonspecific changes were noted in the soft tissues around the mass.
  • The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma.
  • The soft tissues adjacent to the tumor bed did not show major morphological changes.
  • No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size.
  • CONCLUSIONS: This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Melphalan / administration & dosage. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Tumor Necrosis Factor-alpha / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10761796.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


25. Turowski B, Zanella FE: Interventional neuroradiology of the head and neck. Neuroimaging Clin N Am; 2003 Aug;13(3):619-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular interventions are important and helpful for treatment of various pathologies of the head and neck.
  • Interventional neuroradiology of the head and neck includes image-guided biopsies, vessel occlusion, and local chemotherapy.
  • Knowledge of anatomy, functional relationships between intra- and extracranial vessels, and pathology are the basis for therapeutic success.
  • Neuroradiologic imaging, especially CT and MR imaging, and appropriate analysis of angiographic findings help ensure indication for treatment and plan an intervention.
  • Examples of these interventions are: a hemangioma of the hard palate, a juvenile angiofibroma, a hemangiopericytoma, a malignant meningioma, a malignant fibrous histiocytoma, and a glomus tumor.
  • Effective treatment of vascular malformations, such as AV fistulas or angiomas, needs exact occlusion of the fistula or the angiomatous nidus, which is demonstrated in the case of an AV angioma of the base of the tongue.
  • Chemotherapy with local intra-arterial cisplatin combined with intravenous administration of sodium thiosulfate as antidote is indicated as an adjuvant modality in a multimodal regimen of oropharyngeal squamous cell carcinoma or as palliative treatment of recurrent and otherwise untreatable malignant tumors of the head and neck.
  • Palliative treatment of a bleeding oropharyngeal cancer is another example of interventional treatment.
  • Selective treatment, either occluding or pharmacologic, may be preoperative, palliative, or curative.
  • The objective is reduction of surgical risk, improvement of quality of life, or curative therapy of a lesion.
  • Thus, the interventional treatment should not be associated with morbidity or mortality.
  • The benefits, risks, and expected damages of neuroradiologic interventions must be balanced during the informed consent procedure with the patient.
  • [MeSH-major] Head and Neck Neoplasms / radiography. Head and Neck Neoplasms / therapy. Neuroradiography. Radiology, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631695.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


26. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, Crownover R, Marks K, Muschler G, Joyce M, Zehr R, Bukowski R: Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs; 2000 Aug;18(3):253-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas.
  • PURPOSE: To assess the objective response rate, toxicity experienced, progression-free survival, and overall survival of patients with previously untreated advanced soft tissue sarcomas treated with a liposomal doxorubicin formulation (Doxil).
  • METHODS: Patients with metastatic or recurrent soft tissue sarcoma who had received no prior chemotherapy for advanced disease were treated with liposomal doxorubicin (Doxil) according to a two stage accrual design.
  • Leiomyosarcoma (7/15) and malignant fibrous histiocytoma (2/15) were the most common histologic diagnoses.
  • The median time to progression was 1.9 months (range 0.9-6.2).
  • CONCLUSION: Though well-tolerated, Doxil given according to this dose and schedule to patients with advanced soft tissue sarcoma had no significant therapeutic activity.
  • Future investigations of Doxil in soft tissue sarcomas should use a different schedule and dose.
  • [MeSH-major] Doxorubicin / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Carriers. Female. Follow-Up Studies. Humans. Liposomes. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1978 Mar;187(3):332-6 [637593.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Pharm Res. 1993 May;10(5):703-8 [8321835.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1655-9 [2681554.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(4):259-65 [1678995.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Jan;4(1):32-5 [1736976.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2757-62 [7139566.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):862-7 [2201431.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):987-93 [9060537.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):840-50 [3585441.001]
  • [Cites] Biochim Biophys Acta. 1991 Jul 1;1066(1):29-36 [2065067.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2111-7 [9164225.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):851-61 [3295129.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1131-3 [9834828.001]
  • [Cites] Cancer. 1973 Jul;32(1):1-8 [4716773.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 16;187(2):1098-105 [1356335.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):711-6 [9739435.001]
  • [Cites] Cancer. 1974 Jan;33(1):19-27 [4810094.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1269-75 [8315424.001]
  • (PMID = 10958594.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down






Advertisement